Drug Trial Radar · NCT07584057
An Phase I/IIa Clinical Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Preliminary Efficacy of INB301 Injection in Patients With Cancer Cachexia
Last checked: Nov 19, 2026Latest source record: May 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
146
Planned (sponsor's estimate)
Start
May 2026
Primary completion
Feb 2030
Study completion Mar 2030
Sponsor
- Lead sponsor
- Yunnan Baiyao Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter, multiple-dose Phase I/IIa clinical study to assess the safety/tolerability, PK characteristics,immunogenicity, and preliminary efficacy of INB301 Injection in patients with cancer cachexia. The indication to be explored for Phase I is malignant solid tumor with cachexia; Phase IIa will determine the specific study cohort after discussion between the investigator and the sponsor based on the previously obtained clinical trial data and the benefit/risk ratio of the subjects, and preliminarily consider 3 cohorts of tentative 20-30 patients each, including non-small cell lung cancer, pancreatic cancer and colorectal cancer with cachexia.
Conditions
- Cancer Cachexia
Interventions
INB301 InjectionBiological
The screening will be completed within 28 days before administration. Subjects who pass the screening will receive subcutaneous injection of INB301 until the investigator determines that the risk of continued treatment outweighs the benefit, toxicity becomes intolerable, or other criteria for withdrawal or treatment discontinuation are met, whichever occurs first. The end-of-study/early withdrawal visit will be completed at 28 days (±7 days) after the last dose. Each 1 mL of INB301 Injection contains 100 mg of the drug, and 2 mL of the drug can be injected at each subcutaneous injection site, which is at the left and right abdominal subcutaneous tissue, as well as the left and right arm subcutaneous tissue. The specific dose is determined according to the dose cohort. Dosing every 3 or 4 weeks is proposed.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse EventsTime frame: Through study completion, an average of 1 year.
- Mean change in body weight from baseline during each assessment period within 12 weeks.Time frame: Through study completion, an average of 1 year.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
52 Fucheng Road, Haidian District
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.